2027 NCODA Global Oncology & Haematology Congress
March 10, 2027 | 9:00 AM EST
- Home
- Clinical Resources Search
- PQI: Reflex Biomarker Testing in Metastatic Colorectal Cancer: Implementing BRAF and MSI Assessment
Reflex Biomarker Testing in Metastatic Colorectal Cancer: Implementing BRAF and MSI Assessment
About this PQI
This resource outlines a workflow for reflex biomarker testing in first-line metastatic colorectal cancer (mCRC), focusing on BRAF and microsatellite instability (MSI)/mismatch repair (MMR) status to support timely treatment decisions.
How to Use a Positive Quality Intervention (PQI)
Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.
Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.
Find a PQIFind Similar Resources
All Resources
PQI Podcast
PQI Podcast
Patient Education Sheet
PQI
S11 E9: Keep Saying Yes: Living, Advocating, and Finding Purpose with Cancer
Last Updated: 10/25/2026
S11 E6: Finding the Heart of Oncology
Last Updated: 10/25/2026
Bevacizumab and Irinotecan
Last Updated: 07/13/2026
PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer
Last Updated: 05/15/2026
Patient Education Sheet
PQI
Patient Education Sheet
Patient Education Sheet
Encorafenib
Last Updated: 06/26/2026
PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer
Last Updated: 05/15/2026
Encorafenib, Cetuximab and FOLFOX
Last Updated: 01/12/2026
Encorafenib and Binimetinib
Last Updated: 08/09/2024
PQI
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer
Last Updated: 05/15/2026
Cetuximab
Last Updated: 04/08/2026
Cetuximab plus Radiation
Last Updated: 03/09/2026
Encorafenib, Cetuximab and FOLFOX
Last Updated: 01/12/2026
Patient Education Sheet
PQI
Patient Education Sheet
Patient Education Sheet
Encorafenib
Last Updated: 06/26/2026
PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer
Last Updated: 05/15/2026
Encorafenib, Cetuximab and FOLFOX
Last Updated: 01/12/2026
Encorafenib and Binimetinib
Last Updated: 08/09/2024
PQI
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer
Last Updated: 05/15/2026
Cetuximab
Last Updated: 04/08/2026
Cetuximab plus Radiation
Last Updated: 03/09/2026
Encorafenib, Cetuximab and FOLFOX
Last Updated: 01/12/2026
PQI
Patient Education Sheet
PQI
PQI: Amivantamab and Hyaluronidase plus Lazertinib Patient Management
Last Updated: 04/08/2026
Amivantamab and Lazertinib
Last Updated: 03/11/2026
PQI: Prophylaxis and Management of Skin Toxicities with Amivantamab (Rybrevant) and Lazertinib (Lazcluze) Treatment: The COCOON Protocol
Last Updated: 08/07/2025
PQI
PQI
Patient Education Sheet
Patient Education Sheet
PQI: Retifanlimab-dlwr in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal
Last Updated: 10/21/2026
PQI: Ruxolitinib Extended Release for the Management of Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease
Last Updated: 10/21/2026
Rusfertide (Mimrylo)
Last Updated: 10/19/2026
Lirafugratinib (Lyrfigtu)
Last Updated: 10/19/2026